Brief: Gensight To Submit Lumevoq For Marketing Authorisation in EU

Gensight Biologics SA

06/07/2020 06:42

July 6 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS REPORTS SUSTAINED EFFICACY AND SAFETY
AMONG
LHON PATIENTS THREE YEARS AFTER LUMEVOQ® TREATMENT
    * NEW DATA WILL REINFORCE SUBMISSION OF LUMEVOQ® FOR
MARKETING
AUTHORIZATION IN EUROPEAN UNION, WHICH IT INTENDS TO FILE IN
SEPTEMBER 2020

Source text for Eikon:  ID:nBwb0BKJza 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))